Change in Blood Pressure, Weight, and Other Cardiovascular Disease Risk Factors After Switch From Protease Inhibitors to Dolutegravir: Post hoc Analysis of the 48-week Randomised Second-line Switch to Dolutegravir Trial

Loice Achieng Ombajo; Jeremy Penner; Joseph Nkuranga; Victor Omodi; Edwin Otieno; Florentius Ndinya; Simon Wahome; Anton Pozniak

doi:10.1093/cid/ciae514

Change in Blood Pressure, Weight, and Other Cardiovascular Disease Risk Factors After Switch From Protease Inhibitors to Dolutegravir: Post hoc Analysis of the 48-week Randomised Second-line Switch to Dolutegravir Trial

Clin Infect Dis. 2024 Nov 26:ciae514. doi: 10.1093/cid/ciae514. Online ahead of print.

Authors

Loice Achieng Ombajo^{1

2}, Jeremy Penner^{1

3}, Joseph Nkuranga^{1

2}, Victor Omodi^{1

2}, Edwin Otieno^{1

2}, Florentius Ndinya⁴, Simon Wahome⁵, Anton Pozniak⁶

Affiliations

¹ Center for Epidemiological Modelling and Analysis, University of Nairobi, Nairobi, Kenya.
² Department of Clinical Medicine and Therapeutics, University of Nairobi, Nairobi, Kenya.
³ Department of Family Practice, University of British Columbia, Vancouver, Canada.
⁴ Department of Medicine, Jaramogi Oginga Odinga Teaching and Referral Hospital, Kisumu, Kenya.
⁵ Comprehensive Care Center, Kenyatta National Hospital, Nairobi, Kenya.
⁶ Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom.

PMID: 39589132
DOI: 10.1093/cid/ciae514

Abstract

Among 777 virally suppressed adults with human immunodeficiency virus on protease-inhibitor-based second-line antiretroviral regimens randomized 1:1 to switch to dolutegravir or remain on a protease inhibitor, there was no difference in incident hypertension (12% in each arm, P = .868) or change in blood pressure over the 48-week study period.

Keywords: blood pressure; cardiovascular disease risk; incident hypertension; switch to DTG; weight gain.

Abstract

Grants and funding